US: The Most Promising Market for Cancer Vaccines across the Globe

Wednesday 3 October 2012, Amsterdam

According to a new report, "US Cancer Vaccine Market Analysis", though still in infancy, is experiencing a favorable environment due to immense therapeutic potential. Both, the government and private players are actively funding projects aimed at exploring new candidate cancer vaccines. Besides, prophylactic cancer vaccine makers Merck and GSK are being favored and promoted by the government for their vaccine's ability to prevent cervical cancer, a leading cause of mortality due to cancer in females. The study reveals that no new player is expected to hit the US market for prophylactic vaccines in another 5 years at least, making it a lucrative segment for Merck and GSK. Moreover, both the companies are conducting various clinical trials to further strengthen their vaccine's coverage and increase their customer base.

Research Analysis & Highlights

The report entitled "US Cancer Vaccine Market Analysis", provides an effective analysis of the market drivers, current market size and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in future.  Moreover, an in-depth analysis of all the candidate cancer vaccines in various phases of clinical trials for most prevalent cancers in US has been done to identify diverse opportunities for players.

Further, the report provides competitive analysis of promising players in the market along with their key strategies for business expansion. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines to the industry for clinical proceedings of cancer therapeutic vaccines has also been provided.